Alembic Pharmaceuticals through its joint venture (JV) firm Aleor Dermaceuticals has received final USFDA approval for Clobetasol Propionate spray, used to treat plaque psoriasis. The approved product is therapeutically equivalent to the reference listed drug (RLD) product, Clobex spray, 0.05 per cent of Galderma Laboratories LP. Clobetasol Propionate Spray, 0.05 per cent is indicated for the treatment of moderate to severe plaque psoriasis. According to market estimates, Clobetasol Propionate Spray, 0.05 per cent, has an estimated market size of $22 million for the 12 months ending December 2018.
Company Profile : Alembic Pharmaceuticals Ltd